English
Français
Deutsch
Italiano
Português
Русский
Español
ไทย
Türkçe
简体中文
日本語
한국어
हिन्दी
Oppenheimer has downgraded aTyr Pharma Inc (NASDAQ:LIFE) to Perform from Outperform, citing a few material catalysts in the next few quarters. The analyst has also removed the price target of $17.
The analyst says that aTyr is in a fallow period until 2024/25 from the perspective of data readouts.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased
